Cargando…

SAT-280 Body Mass Index at Diagnosis and Hypothalamic-Pituitary Dysfunction during Follow-Up in Childhood Brain Tumor Survivors

Background Childhood Brain Tumor Survivors (CBTS) are at increased risk of hypothalamic-pituitary (HP) dysfunction, which may be caused by radiotherapy , be a complication of the tumor itself or due to brain injury. Being overweighted or underweighted (body mass index (BMI) more than 2 SDS or lower...

Descripción completa

Detalles Bibliográficos
Autores principales: Roessel, Ichelle, Iersel, Laura, Schouten-van Meeteren, Antoinette, Clement, Sarah, Boot, Annemieke, Claahsen-van der Grinten, Hedi, Granzen, Bernd, Han, Sen, Janssens, Geert, Michiels, Erna, Trotsenburg, A. S. Paul, vanderTop, Pieter, van Vuurden, Dannis, Kremer, Leontien, van Santen, Hanneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552651/
http://dx.doi.org/10.1210/js.2019-SAT-280
_version_ 1783424642364473344
author Roessel, Ichelle
Iersel, Laura
Schouten-van Meeteren, Antoinette
Clement, Sarah
Boot, Annemieke
Claahsen-van der Grinten, Hedi
Granzen, Bernd
Han, Sen
Janssens, Geert
Michiels, Erna
Trotsenburg, A. S. Paul
vanderTop, Pieter
van Vuurden, Dannis
Kremer, Leontien
van Santen, Hanneke
author_facet Roessel, Ichelle
Iersel, Laura
Schouten-van Meeteren, Antoinette
Clement, Sarah
Boot, Annemieke
Claahsen-van der Grinten, Hedi
Granzen, Bernd
Han, Sen
Janssens, Geert
Michiels, Erna
Trotsenburg, A. S. Paul
vanderTop, Pieter
van Vuurden, Dannis
Kremer, Leontien
van Santen, Hanneke
author_sort Roessel, Ichelle
collection PubMed
description Background Childhood Brain Tumor Survivors (CBTS) are at increased risk of hypothalamic-pituitary (HP) dysfunction, which may be caused by radiotherapy , be a complication of the tumor itself or due to brain injury. Being overweighted or underweighted (body mass index (BMI) more than 2 SDS or lower than -2 SDS, respectively) at brain tumor diagnosis may reflect early hypothalamic dysfunction and may be a risk factor to develop HP dysfunction during follow-up. This has, to date, not been investigated. The objective of this study was to examine whether BMI at brain tumor diagnosis is associated with the development of HP dysfunction, independent of brain tumor treatment. Methods Children surviving a brain tumor, excluding craniopharyngioma or a pituitary tumor, for minimally two years, in whom BMI at diagnosis of their brain tumor had been recorded were included from a previous cohort study (n=685 of 718). Odds-ratios (OR) for developing HP dysfunction were calculated using multivariable logistic regression, including BMI at diagnosis, gender, age at follow-up, radiotherapy, histology, location of the primary tumor, hydrocephalus and state of disease. Results Of all, 10.8% (n=74) was overweighted and 5.0% (n=34) was underweighted at diagnosis. Median follow-up time was 7.1 years (5.0-9.6). Being overweighted or underweighted at diagnosis was significantly associated with the development of HP dysfunction (anterior or posterior pituitary deficiency or central precocious puberty , OR 2.43, 95% CI 1.46-4.05) and obesity at follow-up (OR 3.75, 95% CI 2.36-5.97).Development of HP dysfunction was also significantly associated with radiotherapy (OR 11.25, 95% CI 6.76-18.72) and location of primary tumor (OR 2.24, 95% CI 1.60-3.13). In children not treated with radiotherapy (n=430), underweight and overweight at brain tumor diagnosis were also both significantly associated with HP dysfunction and precocious puberty (OR 2.91, 95% CI 1.16-7.28 and 3.00 , 95% CI 1.12-8.01, respectively). In this group, other significant risk factors for HP dysfunction included location of primary tumor (OR 8.90, 95% CI 4.11-19.24), hydrocephalus (2.27, 95% CI 1.06-4.88) and state of disease at follow-up (OR 6.38, 95% CI 1.37-29.58). Conclusions Being overweighted or underweighted at brain tumor diagnosis in childhood is associated with the development of anterior pituitary deficiencies, posterior pituitary deficiencies and CPP, independently of given treatment. This suggests that in these children hypothalamic dysfunction may already be present at brain tumor diagnosis. These findings may be used for future studies on hypothalamic dysfunction in CBTS and can be used to develop recommendations on monitoring the development of pituitary disorders in CBTS.
format Online
Article
Text
id pubmed-6552651
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65526512019-06-13 SAT-280 Body Mass Index at Diagnosis and Hypothalamic-Pituitary Dysfunction during Follow-Up in Childhood Brain Tumor Survivors Roessel, Ichelle Iersel, Laura Schouten-van Meeteren, Antoinette Clement, Sarah Boot, Annemieke Claahsen-van der Grinten, Hedi Granzen, Bernd Han, Sen Janssens, Geert Michiels, Erna Trotsenburg, A. S. Paul vanderTop, Pieter van Vuurden, Dannis Kremer, Leontien van Santen, Hanneke J Endocr Soc Pediatric Endocrinology Background Childhood Brain Tumor Survivors (CBTS) are at increased risk of hypothalamic-pituitary (HP) dysfunction, which may be caused by radiotherapy , be a complication of the tumor itself or due to brain injury. Being overweighted or underweighted (body mass index (BMI) more than 2 SDS or lower than -2 SDS, respectively) at brain tumor diagnosis may reflect early hypothalamic dysfunction and may be a risk factor to develop HP dysfunction during follow-up. This has, to date, not been investigated. The objective of this study was to examine whether BMI at brain tumor diagnosis is associated with the development of HP dysfunction, independent of brain tumor treatment. Methods Children surviving a brain tumor, excluding craniopharyngioma or a pituitary tumor, for minimally two years, in whom BMI at diagnosis of their brain tumor had been recorded were included from a previous cohort study (n=685 of 718). Odds-ratios (OR) for developing HP dysfunction were calculated using multivariable logistic regression, including BMI at diagnosis, gender, age at follow-up, radiotherapy, histology, location of the primary tumor, hydrocephalus and state of disease. Results Of all, 10.8% (n=74) was overweighted and 5.0% (n=34) was underweighted at diagnosis. Median follow-up time was 7.1 years (5.0-9.6). Being overweighted or underweighted at diagnosis was significantly associated with the development of HP dysfunction (anterior or posterior pituitary deficiency or central precocious puberty , OR 2.43, 95% CI 1.46-4.05) and obesity at follow-up (OR 3.75, 95% CI 2.36-5.97).Development of HP dysfunction was also significantly associated with radiotherapy (OR 11.25, 95% CI 6.76-18.72) and location of primary tumor (OR 2.24, 95% CI 1.60-3.13). In children not treated with radiotherapy (n=430), underweight and overweight at brain tumor diagnosis were also both significantly associated with HP dysfunction and precocious puberty (OR 2.91, 95% CI 1.16-7.28 and 3.00 , 95% CI 1.12-8.01, respectively). In this group, other significant risk factors for HP dysfunction included location of primary tumor (OR 8.90, 95% CI 4.11-19.24), hydrocephalus (2.27, 95% CI 1.06-4.88) and state of disease at follow-up (OR 6.38, 95% CI 1.37-29.58). Conclusions Being overweighted or underweighted at brain tumor diagnosis in childhood is associated with the development of anterior pituitary deficiencies, posterior pituitary deficiencies and CPP, independently of given treatment. This suggests that in these children hypothalamic dysfunction may already be present at brain tumor diagnosis. These findings may be used for future studies on hypothalamic dysfunction in CBTS and can be used to develop recommendations on monitoring the development of pituitary disorders in CBTS. Endocrine Society 2019-04-30 /pmc/articles/PMC6552651/ http://dx.doi.org/10.1210/js.2019-SAT-280 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Pediatric Endocrinology
Roessel, Ichelle
Iersel, Laura
Schouten-van Meeteren, Antoinette
Clement, Sarah
Boot, Annemieke
Claahsen-van der Grinten, Hedi
Granzen, Bernd
Han, Sen
Janssens, Geert
Michiels, Erna
Trotsenburg, A. S. Paul
vanderTop, Pieter
van Vuurden, Dannis
Kremer, Leontien
van Santen, Hanneke
SAT-280 Body Mass Index at Diagnosis and Hypothalamic-Pituitary Dysfunction during Follow-Up in Childhood Brain Tumor Survivors
title SAT-280 Body Mass Index at Diagnosis and Hypothalamic-Pituitary Dysfunction during Follow-Up in Childhood Brain Tumor Survivors
title_full SAT-280 Body Mass Index at Diagnosis and Hypothalamic-Pituitary Dysfunction during Follow-Up in Childhood Brain Tumor Survivors
title_fullStr SAT-280 Body Mass Index at Diagnosis and Hypothalamic-Pituitary Dysfunction during Follow-Up in Childhood Brain Tumor Survivors
title_full_unstemmed SAT-280 Body Mass Index at Diagnosis and Hypothalamic-Pituitary Dysfunction during Follow-Up in Childhood Brain Tumor Survivors
title_short SAT-280 Body Mass Index at Diagnosis and Hypothalamic-Pituitary Dysfunction during Follow-Up in Childhood Brain Tumor Survivors
title_sort sat-280 body mass index at diagnosis and hypothalamic-pituitary dysfunction during follow-up in childhood brain tumor survivors
topic Pediatric Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552651/
http://dx.doi.org/10.1210/js.2019-SAT-280
work_keys_str_mv AT roesselichelle sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT iersellaura sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT schoutenvanmeeterenantoinette sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT clementsarah sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT bootannemieke sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT claahsenvandergrintenhedi sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT granzenbernd sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT hansen sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT janssensgeert sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT michielserna sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT trotsenburgaspaul sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT vandertoppieter sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT vanvuurdendannis sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT kremerleontien sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors
AT vansantenhanneke sat280bodymassindexatdiagnosisandhypothalamicpituitarydysfunctionduringfollowupinchildhoodbraintumorsurvivors